This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

Atazanavir, Lamivudine, Ritonavir, Tenofovir Disoproxil Fumarate belong to the class of antiretroviral or antiviral medicine which treats HIV (human immunodeficiency virus) infection.

Mechanism of Action of undefined

Atazanavir and Ritonavir inhibit the viral enzyme protease. Lamivudine and Tenofovir disoproxil fumarate inhibit the enzyme reverse transcriptase; inhibition of these enzymes blocks the reproduction of the virus and prevents the release of viral particles in the body to treat the HIV infection.

Uses of undefined

Atazanavir, Lamivudine, Ritonavir, Tenofovir Disoproxil Fumarate has been developed to treat Human Immunodeficiency Virus (HIV-1).  It is a nucleotide reverse transcriptase inhibitor (NRTI) and works by inhibiting the enzymes (HIV reverse transcriptase) important for virus replication. This tablet is not studied in patients over 65 years of age.

undefined Drug administaration and Dosage available

Atazanavir, Lamivudine, Ritonavir, Tenofovir Disoproxil Fumarate are film-coated tablets. The usual recommended dosage of this medication is one tablet every day, with or without food. Your physician will choose the dosage and administration frequency based on the medical condition because it differs for each person. Do not crush, chew or break the tablet. 

Warnings, Precautions and Side Effects of undefined

Warnings

Do not take this medication if you have experienced hypersensitivity reactions to Atazanavir, Lamivudine, Ritonavir, Tenofovir Disoproxil Fumarate, or any of its ingredients. During the Atazanavir, Lamivudine, Ritonavir, Tenofovir Disoproxil Fumarate Tablet treatment, your doctor may periodically monitor your blood counts, bone mineral density, liver and kidney parameters to prevent serious complications. Report to your doctor if you have had a history of heart failure, pancreatitis, bone disease, fractures, liver or kidney problems.

Precautions

Adults of childbearing potential should consider using an effective contraceptive to prevent unwanted pregnancy. If you are pregnant or think you might be pregnant, your physician might suggest an alternative treatment, as this medication is not recommended during early pregnancy. Breastfeeding is not recommended due to the potential transmission of HIV from the mother to the baby.

Side Effects

The common side effects that are likely to occur while you are on the treatment with Atazanavir, Lamivudine, Ritonavir, Tenofovir Disoproxil Fumarate tablet are headach, stomach pain, tiredness, bloating, flatulence, low phosphate levels in the blood, diarrhea,  dizziness, joint pain, sickness, rash, weakness.

Some serious adverse reactions include pancreas problems, kidney damage, deep, rapid breathing, drowsiness, nausea, vomiting, lactic acidosis (excess lactic acid), infection, increased liver enzymesIf you experience any allergic reactions after taking this tablet, report to your doctor immediately.

Word Of Advice

Atazanavir, Lamivudine, Ritonavir, Tenofovir Disoproxil Fumarate can make you feel dizzy and tired. Hence, you should avoid driving or handling machines during this treatment. Be sure to consult your healthcare provider before taking the tablet. This medication does not reduce the risk of transmitting HIV to others through sexual contact or blood contamination. You must continue the medication to avoid this complication.

Frequently Asked Question

References

  1. Goodman & Gilman’s, The Pharmacological Basics of Therapeutics, Antiretroviral agents and treatment of HIV infection, 12th edition, 2011, 1632-1634.
  2. KD Tripathi, Essentials of Medical Pharmacology, Antiviral drugs, 7th edition, 2013, 809-810.
  3. Cipla Ltd, US Food and Drug Administration, [ Revised on October 2017] [ Accessed on 14th June 2021], https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/206451PI.pdf
  4. Cipla (EU) Limited, Electronic Medicines Compendium (emc), [ Revised on October 2017] [ Accessed on 14th June 2021], https://www.medicines.org.uk/emc/files/pil.10500.pdf

Disclaimer

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you are eligible to receive this treatment.